ORIGINAL ARTICLE
Expression of p16 protein in breast cancer
1
Department of Pathology, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
2
Department of Community Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
3
Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
4
Department of Pathology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
Submission date: 2023-03-10
Final revision date: 2023-06-23
Acceptance date: 2024-01-11
Publication date: 2024-03-09
Pol J Pathol 2024;75(1):19-24
KEYWORDS
TOPICS
ABSTRACT
Breast cancer is the most common cancer and a leading cause of death in women in Saudi Arabia. P16 is a tumour suppressor gene that plays a crucial role in regulating cell cycle. Several studies have investigated the significance of p16 expression in various cancer types. However, the significance of p16 in breast cancer remains controversial and insufficiently studied.
The present study aims to examine the association between p16 expression and clinicopathological factors in breast cancer using immunohistochemistry staining.
The study utilised 475 prospectively collected tissue samples from 475 women with breast cancer in Saudi Arabia.
Nuclear and cytoplasmic immunohistochemical staining of p16 was observed in 338 (71%) of the cases and showed significant direct associations with adverse tumour features, including high tumour grade (p < 0.0001), negative oestrogen receptor/progesterone receptor status (p < 0.001), and lymph node metastasis (p = 0.02).
Our study revealed a significant association between p16 protein expression and the established negative prognostic parameters in breast carcinoma including tumour grade, lymph node metastasis, and oestrogen receptor and progesterone receptor status.
The present study aims to examine the association between p16 expression and clinicopathological factors in breast cancer using immunohistochemistry staining.
The study utilised 475 prospectively collected tissue samples from 475 women with breast cancer in Saudi Arabia.
Nuclear and cytoplasmic immunohistochemical staining of p16 was observed in 338 (71%) of the cases and showed significant direct associations with adverse tumour features, including high tumour grade (p < 0.0001), negative oestrogen receptor/progesterone receptor status (p < 0.001), and lymph node metastasis (p = 0.02).
Our study revealed a significant association between p16 protein expression and the established negative prognostic parameters in breast carcinoma including tumour grade, lymph node metastasis, and oestrogen receptor and progesterone receptor status.
REFERENCES (21)
1.
Al Diab A, Qureshi S, Al Saleh KA, Al Qahtani FH, Aleem A, Algamdi M. Review on breast cancer in the Kingdom of Saudi Arabia. Middle E J Sci Res 2013; 14: 532-543.
2.
Ashareef B, Yaseen W, Jawa W, et al. Breast cancer awareness among female school teachers in Saudi Arabia: a population based survey. Asian Pac J Cancer Prev 2020; 21: 337-342.
3.
Peurala E, Koivunen P, Haapasaari K, Bloigu R, Jukkola-Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 2013; 15: 1-10.
4.
Salih MM, Higgo AA, Eed EM. Prognostic significance of p16 protein expression in breast cancer. In Vivo 2022; 36: 336-340.
5.
Abou-Bakr AA, Eldweny HI. P16 expression correlates with basal-like triple-negative breast carcinoma. Ecancermedicalscience 2013; 7: 317.
6.
Hashmi AA, Naz S, Hashmi SK, et al. Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer. BMC Clin Pathol 2018; 18: 1-11.
7.
Swain S. Triple-negative breast cancer: metastatic risk and role of platinum agents. Presented at the Annual Meeting of the American Society for Clinical Oncology, Clinical Science Symposium, Chicago, June 3, 2008.
8.
Arima Y, Hayashi N, Hayashi H, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor‐negative breast cancer. Int J Cancer 2012; 130: 2568-2579.
9.
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
10.
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
11.
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
12.
Milde-Langosch K, Bamberger A, Rieck G, Kelp B, Löning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001; 67: 61-70.
13.
Lebok P, Roming M, Kluth M, et al. P16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget 2016; 7: 81322.
14.
Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10: 1-13.
15.
Shan M, Zhang X, Liu X, et al. P16 and p53 play distinct roles in different subtypes of breast cancer. PloS One 2013; 8: e76408.
16.
Golmohammadi R, Elyasi H, Golmohammadi M. Relationship between P16 expression and breast cancer using histology and immunohistochemistry. J Mazandaran Univ Med Sci 2017; 27: 181-186.
17.
Geradts J, Wilson PA. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol 1996; 149: 15-20.
18.
Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006-6011.
19.
Witkiewicz AK, Rivadeneira DB, Ertel A, et al. Association of RB/p16-pathway perturbations with DCIS recurrence: Dependence on tumor versus tissue microenvironment. Am J Pathol 2011; 179: 1171-1178.
20.
Karray-Chouayekh S, Baccouche S, Khabir A, et al. Prognostic significance of p16INK4a/p53 in tunisian patients with breast carcinoma. Acta Histochem 2011; 113: 508-513.
21.
Hui R, Macmillan RD, Kenny FS, et al. INK4a gene expression and methylation in primary breast cancer: Overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000; 6: 2777-2787.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
